 |
|
Scleroderma Outlook Improves as Survival Increases
July 13, 2007Washington, D.C. -- Individuals with scleroderma are living significantly longer today, compared with 30 years ago, and the physicians who treat this rare disease of connective tissue hope the newer drugs now on the market may extend lives even further.
Scleroderma, a rare autoimmune disorder of unknown origin, results when collagen builds up in the body's connective tissue and causes thickening of the skin. In the chronic and often progressive systemic form, scleroderma causes stiff joints and hardening of the internal organs and blood vessels.
In the July issue of the journal Annals of the Rheumatic Diseases, Georgetown University Medical Center professor Virginia Steen, M.D., studied 2,000 patients with scleroderma (also known as systemic sclerosis) treated between 1972 and 2001 at the University of Pittsburgh and found that 10-year survival steadily improved over those years by 12 percent-- from 54 percent to 66 percent.
"This is really good progress, which we hope to improve upon," said Steen, a leading expert on the disorder who has helped make Georgetown University Hospital a national treatment center for scleroderma. In the 1980s, while at the University of Pittsburgh, she developed a natural history database of scleroderma patients and this database has continued to evolve into the largest in the United States.
The reason overall mortality has dropped, Steen says, is partly because a class of medications, angiotensin converting enzyme (ACE) inhibitors became available which dramatically improved the treatment of renal crisis. Renal crisis used to be almost always fatal and now it is a very treatable complication of scleroderma, she said.
Now pulmonary arterial hypertension and pulmonary fibrosis, a condition that is traditionally the second-most frequent cause of death, is responsible for most of the mortality, but these conditions may be increasingly treatable, she said. Patients may develop either disorder, or both.
"Before, it was kidney and then lung disorders that affected most of our patients, and now that we have successfully treated the kidneys, mortality due to lung disease has become the issue," Steen said. "We are working on ways to use the newer medications to help treat these disorders, hoping to further improve overall survival."
While all scleroderma-related disorders are believed to affect as many as 900,000 people in the United States, only between 40,000 and 165,000 are diagnosed with systemic scleroderma, according to the National Institutes of Health (NIH). Like all scleroderma disorders, systemic scleroderma affects more women than men, and varies in severity.
In this study, Steen collaborated with co-author Thomas Medsger, M.D., professor of medicine at the University of Pittsburgh to study patients with systemic scleroderma enrolled in the registry. They studied patients evaluated at the University of Pittsburgh between 1972 and 2001, dividing them into five-year time periods, depending on when they were seen.
They found survival improved in each of the five-year periods, and that the frequency of death due to renal crisis significantly decreased over the 30 years, from 42 percent to 6 percent. But the proportion of patients who died from pulmonary fibrosis increased from 6 percent to 33 percent, Steen said. The frequency of pulmonary hypertension also increased, but there was no change in gastrointestinal and heart-related deaths.
"Use of ACE inhibitors made all the difference in saving patients from renal failure, and now it is important that physicians use drugs now available to treat lung disorders and researchers continue to search for new therapies," Steen said.
Georgetown University Medical Center
"This is really good progress, which we hope to improve upon," said Steen, a leading expert on the disorder who has helped make Georgetown University Hospital a national treatment center for scleroderma. In the 1980s, while at the University of Pittsburgh, she developed a natural history database of scleroderma patients and this database has continued to evolve into the largest in the United States.
The reason overall mortality has dropped, Steen says, is partly because a class of medications, angiotensin converting enzyme (ACE) inhibitors became available which dramatically improved the treatment of renal crisis. Renal crisis used to be almost always fatal and now it is a very treatable complication of scleroderma, she said.
Now pulmonary arterial hypertension and pulmonary fibrosis, a condition that is traditionally the second-most frequent cause of death, is responsible for most of the mortality, but these conditions may be increasingly treatable, she said. Patients may develop either disorder, or both.
"Before, it was kidney and then lung disorders that affected most of our patients, and now that we have successfully treated the kidneys, mortality due to lung disease has become the issue," Steen said. "We are working on ways to use the newer medications to help treat these disorders, hoping to further improve overall survival."
While all scleroderma-related disorders are believed to affect as many as 900,000 people in the United States, only between 40,000 and 165,000 are diagnosed with systemic scleroderma, according to the National Institutes of Health (NIH). Like all scleroderma disorders, systemic scleroderma affects more women than men, and varies in severity.
In this study, Steen collaborated with co-author Thomas Medsger, M.D., professor of medicine at the University of Pittsburgh to study patients with systemic scleroderma enrolled in the registry. They studied patients evaluated at the University of Pittsburgh between 1972 and 2001, dividing them into five-year time periods, depending on when they were seen.
They found survival improved in each of the five-year periods, and that the frequency of death due to renal crisis significantly decreased over the 30 years, from 42 percent to 6 percent. But the proportion of patients who died from pulmonary fibrosis increased from 6 percent to 33 percent, Steen said. The frequency of pulmonary hypertension also increased, but there was no change in gastrointestinal and heart-related deaths.
"Use of ACE inhibitors made all the difference in saving patients from renal failure, and now it is important that physicians use drugs now available to treat lung disorders and researchers continue to search for new therapies," Steen said.
Georgetown University Medical Center
Scleroderma Current Events and Scleroderma News RSSGeneticists Hunt for Scleroderma Triggers
At its most benign, the autoimmune disease scleroderma can discolor parts of the skin of its sufferers. At its most pernicious, it can thicken and harden their skin, their blood vessels, and their internal organs before, in many cases, killing them.
Drug could provide first treatment for scleroderma
Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive.
BUSM researchers identify better laser for treating facial spider veins
Researchers from Boston University School of Medicine (BUSM) have concluded that the 940nm wavelength laser is superior for treating facial spider veins (telangiectasias) as compared to the 532nm wavelength laser.
Endothelin-Related Drugs Benefit Patients With Pulmonary Hypertension
Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.
International conference on endothelin
One of the most intriguing developments in recent medical science is the discovery of the human chemical endothelin (ET).
Survival instincts propel 'difficult patient' to insist on quality care
Michelle Mayer had to become a "difficult patient" before she could get her physicians to accurately diagnose the disease that was destroying her health.
Dartmouth researchers discover gene signatures for scleroderma
Distinct genetic profiles can discern different groups of patients with scleroderma, a vexing autoimmune disease in which the body turns against itself, Dartmouth Medical School researchers report.
UCSF marks a milestone with 500th transplant in heart and lung program
UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.
Researchers show that fibrosis can be stopped, cured and reversed
University of California, San Diego researchers have proven in animal studies that fibrosis in the liver can be not only stopped, but reversed.
Green tea may help prevent autoimmune diseases
Green tea may help protect against autoimmune disease, Medical College of Georgia researchers say.
More Scleroderma Current Events and Scleroderma News Articles
 |
The Scleroderma Book: A Guide for Patients and Families by Maureen D. Mayes M.D. (Author) The Scleroderma Book has long been considered the leading source of information for patients suffering with this disease. Now comes the Second Edition of this highly respected volume, extensively revised by Maureen Mayes, M.D., the leading authority in this field. Writing specifically for patients and their families, Dr. Mayes draws on her extensive experience treating scleroderma to provide up-to-date, practical information that will help patients manage their symptoms and improve their quality of life. Dr. Mayes begins with an easily accessible description of the basic facts, distinguishing between the many manifestations of the disease, ranging from localized scleroderma (small patches of hardened skin, most common in children, which tend to clear up over time) to systemic scleroderma,... |
 |
Scleroderma: The Proven Therapy that Can Save Your Life by Henry Scammell (Author) Scleroderma, which affects as many as 400,000 Americans, starts off like skin cancer but is far more deadly. This new edition is updated with new information about the best therapy for this disease, including the results of the landmark first, and a new, second clinical trial of the only therapy to report reversal and remission of this deadly disease. |
 |
The First Year: Scleroderma: An Essential Guide for the Newly Diagnosed (The First Year Series) by Karen Gottesman (Author), M.D. Daniel E. Furst (Foreword) Scleroderma-a chronic autoimmune condition that causes hardening, thickening, or tightening of the skin and attacks the heart, lungs, kidneys, and gastrointestinal tract-is extraordinarily difficult to diagnose and can take a huge toll on the psychological well-being of the individual. From the first moment of her diagnosis, author Karen Gottesman took charge and educated herself on every aspect of her condition. Now, as a "patient-expert," she guides those newly diagnosed step by step through their first year with scleroderma. She provides crucial information about the nature of the disease, treatment options, diet, exercise, social concerns, emotional issues, networking with others, and much more. The First Year™-Scleroderma is illustrated with charts and tables, and offers an... |
 |
A Journey Towards Health ... Reversing Scleroderma by Jane M. Parker (Author), Victor Dyment (Author), Elieba Levine (Editor) Answers do exist for seemingly incurable diseases. The information contained in this book applies to a diverse variety of conditions ranging from ADD, Autism, Scleroderma, and MS to psoriasis and eczema. We all have the ability to reach good health by changing to the correct materials such as dental, clothing and furniture. This book follows Jane Parker's journey from the diagnosis of systemic Scleroderma, a fatal autoimmune disease, to good health. After a year of unanswered questions, numerous doctors and alternative practitioners, she finally received a correct diagnosis of Scleroderma. In researching the disease she found there was no known way to cure it. All existing information held no hope for survival – and definitely none for a reversal, but this... |
 |
Voices of Scleroderma by International Scleroderma Network (Author) “I highly recommend this book for patients, caregivers, and medical professionals who want quality medical information and support for scleroderma and related illnesses. “Access to high quality reliable modern information is crucial to patient well-being and outcomes. The realization that ‘you ARE NOT alone’ has therapeutic value in its own right. “The nonprofit International Scleroderma Network (ISN) and its website at www.sclero.org enjoys a well-deserved reputation for top-notch medical and support information and services from both the patient and medical organizations throughout the world. Each book in this series features enlightening articles from esteemed scleroderma researchers as well as over 100 unique patient and caregiver stories from 16 countries and in 5... |
 |
Connective Tissue Diseases: Holistic Therapy Options--Sjoegren¿s Syndrome; Systemic Sclerosis - Scleroderma; Systemic Lupus Erythematosus; Discoid Lupus Erythematosus; Secondary and Primary Raynaud¿s phenomenon; Raynaud¿s Disease; Polymyositis ¿ Dermatomyositis by Hannelore Helbing-Sheafe (Author) Hannelore Helbing-Sheafe’s constant struggle with her health was a powerful motivator to investigate possible ways to help herself and others. The focus of her practice was always on finding the cause of the problem and instructing patients in using correct nutrients and/or natural medicine and therapy to correct and reverse existing health problems. Her main focus has been to seek balance in all body systems. Connective Tissue Diseases - Holistic Therapy Options provides valuable information about holistic therapy options for patients afflicted with connective tissue (collagen) problems. Detailed information is given regarding current medical diagnostic procedures and treatment, followed by holistic therapy options. The book also provides details about the multiple,... |
 |
Scleroderma, An Issue of Rheumatic Disease Clinics (The Clinics: Internal Medicine) by Fredrick M. Wigley (Author) Scleroderma is unique among our rheumatic diseases both in its clinical expression and its resistance to recovery when using our usual anti-inflammatory medications. The reason for this difference is now becoming apparent as the biology of the scleroderma process is better understood. It is now recognized that the disease expression is quite heterogeneous and that several different clinical but distinct phenotypes exists. This issue of Rheumatic Disease Clinics provides a concise update of developments in this area of study and covers topics such as vascular disease in scleroderma, diagnosis, management of the disease, genetics, novel treatments, scleroderma-like disorders, and its effect on the heart and lungs. |
 |
The Story of Jean: Ending Her Journey At age 23, Jean Stevens was diagnosed with the rare disease Scleroderma, which affects the body's ability to produce the collagen needed to give the skin elasticity. Without collagen, facial features become transfixed, joints stiffen and eventually the body's vital organs can eventually harden. Jean faced the disease with the vibrancy and determination that was more than admirable -- it was inspirational. Yet a positive attitude wasn't enough to deflect the onslaught of yet another disease, this time cancer. The Story of Jean is a remarkable story about an equally remarkable woman afflicted with more than her share of trials. But Jean also considered herself blessed with more than her share of friends. With no family to stand with her, Jean's friends became her adopted family, her... |
 |
Clearly Charming Light Blue Ribbon Prostate, Lung Cancer, Trisomy 18, Scleroderma Italian Charm by Clearly Charming Light blue ribbon stands for prostate cancer, and Scleroderma awareness. It will make a great addition to your Italian charm bracelet or a perfect personalized gift. Commemorate special occasions, capture memorable moments, or simply show off your birthstone by creating your own original Italian charm bracelet. Add Clearly Charming premium quality interlocking modular Italian charm links to your Italian Charm Bracelet and create your own memory bracelet. |
 |
Voices of Scleroderma Volume 1 by International Scleroderma Network (Author) A comprehensive book of scleroderma medical and support information, with articles by world experts in scleroderma and caregiving, as well as over 100 true stories from those affected by scleroderma. |
| © 2009 BrightSurf.com |